Results from the phase 3 INTerpath-001 trial, presented at the 2026 ESMO Congress, showed that adding an individualized mRNA neoantigen therapy to pembrolizumab reduced the risk of recurrence or death by 42% in patients with resected stage IIB to IV melanoma. The combination also reduced the risk of distant metastasis or death by 38%, according to data discussed by Karen E. Knudsen, PhD, CEO of the Parker Institute for Cancer Immunotherapy.
From Dismissed Concept to Medical Platform
Fifteen years ago, most scientists considered messenger RNA too unstable to serve as the basis for a new class of medicines. The biotech industry had largely bet on DNA, which was viewed as more reliable. Moderna CEO Stéphane Bancel has reflected that using mRNA as a drug was once considered “crazy,” but advances in lipid nanoparticle delivery changed that trajectory. The technology matured rapidly during the COVID-19 pandemic, where mRNA vaccines saved an estimated 2 million lives globally from 2021 to 2024. That real-world validation turned a molecular misfit into what Bancel describes as a versatile platform for developing a variety of treatments in a plug-and-play scenario.
How mRNA Vaccines Instruct the Immune System
Unlike traditional vaccines that introduce a weakened pathogen or protein fragments, mRNA vaccines deliver antigen-encoding molecules directly into cells. The cells then use these strands as blueprints to build specific proteins — in this case, neoantigens unique to a patient’s tumor. These proteins stimulate an adaptive immune response, teaching the body to identify and destroy malignant cells bearing those markers. Lipid nanoparticles encapsulate the mRNA to protect the fragile strands and facilitate their absorption into cells. Because mRNA does not interact with the patient’s genomic DNA, it avoids a theoretical safety concern associated with DNA-based approaches.
Advantages Over Traditional Approaches
The platform offers three distinct advantages for personalized oncology: ease of design, speed of production, and the ability to induce both cellular and humoral immunity. Once a tumor’s genetic sequence is known, a custom vaccine can be manufactured rapidly — a critical factor when treating aggressive cancers. The technology also allows the immune system to mount a dual attack: T cells target infected or malignant cells directly, while antibodies provide a secondary layer of defense. Cancer cells often evade detection by suppressing T-cell activity through immune checkpoints; mRNA vaccines aim to overcome this by training the immune system to recognize novel target structures on tumors that the body might otherwise ignore.
Clinical Evidence: The INTerpath-001 Trial
In the INTerpath-001 trial, the individualized mRNA vaccine intismeran autogene was combined with pembrolizumab (Keytruda) and compared to pembrolizumab alone. The hazard ratio for recurrence-free survival was 0.58 (95% CI, 0.45–0.75; P < .001), representing a 42% reduction in risk. For distant metastasis-free survival, the hazard ratio was 0.62 (95% CI, 0.45–0.85; P = .002), a 38% reduction. Knudsen noted the regimen's tolerability, with patients gaining benefit and little added toxicity. A prespecified sensitivity analysis revealed that recurrence-free survival did not differ between arms during the first six months (HR, 0.99) but separated significantly thereafter (HR, 0.42), a pattern consistent with the time a therapeutic vaccine needs to durably train the immune system. Overall survival data remain immature at this first interim analysis.
The Path Forward for Personalized Oncology
BioNTech, a pioneer in mRNA cancer research, is now pivoting its business strategy toward the commercialization of mRNA-based oncology treatments in the United States and other major global markets. That project focuses on identifying tumor-specific peptides that are not widely present in healthy tissue — a key challenge given that liver tumors differ considerably between patients. Bancel has indicated that similarly encouraging results for a rare disease program are expected by year-end. The encouraging part is that multiple well-conducted trials are now showing a path forward for therapeutic cancer vaccines. Patients should talk to your doctor or oncologist about whether these emerging options may be appropriate for their care.
Sources
- Phase 3 Results Point to a Path Forward for Cancer Vaccines | Targeted Onc – Immunotherapy, Biomarkers, and Cancer Pathways
- MRNA vaccine
- Is the mRNA Influenza Vaccine More Efficacious in Older Adults? | Contagion Live
- The Next Chapter of mRNA
- EU-funded project develops mRNA vaccine targeting liver cancer
- BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027? | The Motley Fool
Photo: Bratchykova Yuliia (CC BY 4.0)
